Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2024

Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2024

DelveInsight’s, “Janus Kinase (JAK) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Janus Kinase (JAK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Janus Kinase (JAK) Inhibitors Understanding

Janus Kinase (JAK) Inhibitors: Overview

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing. Cytokines play key roles in controlling cell growth and the immune response. Many cytokines function by binding to and activating type I and type II cytokine receptors. These receptors in turn rely on the Janus kinase (JAK) family of enzymes for signal transduction. Hence drugs that inhibit the activity of these Janus kinases block cytokine signalling. More specifically, Janus kinases phosphorylate activated cytokine receptors. These phosphorylated receptors in turn recruit STAT transcription factors which modulate gene transcription

• Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts.
• Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. In addition, they are easy to reach the inside of cells and directly inhibit intracellular signaling molecules.
• JAK inhibitors belong to a family of medicine called DMARDs (disease-modifying antirheumatic drugs). Thre JAK inhibitors, baricitinib (Olumiant), tofacitinib (Xeljanz), and upadacitinib (Rinvoq), are approved by the FDA to treat rheumatoid arthritis.

Janus Kinase (JAK) Inhibitors Emerging Drugs Chapters

This segment of the Janus Kinase (JAK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Janus Kinase (JAK) Inhibitors Emerging Drugs

• Gusacitinib - Asana BioSciences

Gusacitinib (ASN002) is a potent inhibitor of the Janus kinase (JAK) family (JAK1, JAK2, JAK3 and TYK2) and spleen tyrosine kinase (SYK). Autoimmune, inflammatory and immunological-based diseases, including atopic dermatitis, have complex pathogeneses that involve interactions between multiple cytokines and immune cells. JAK kinases play a significant role in these inflammatory conditions. The JAK kinases family (JAK1, JAK2, JAK3 and TYK2) is involved in signaling pathways of the Th2, Th22, Th1 and Th17 cytokines involved in AD pathogenesis. Hence, JAK kinases play a significant role in inflammatory conditions, particularly those driven by cytokines. SYK is a vital mediator of immunoreceptor signaling in macrophages, neutrophils, mast cells, and B cells. SYK mediated signaling leads to increased release of inflammatory cytokines, lipid mediators, and various proteases. Activated B cells and macrophages also act as antigen presenting cells and potent activators of T cells in inflammatory conditions. SYK also plays a critical role in IL-17R signaling in keratinocytes and in keratinocyte proliferation and terminal differentiation.

Further product details are provided in the report……..

Janus Kinase (JAK) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Janus Kinase (JAK) Inhibitors

There are approx. 50+ key companies which are developing the Janus Kinase (JAK) Inhibitors. The companies which have their Janus Kinase (JAK) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Asana BioSciences.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Janus Kinase (JAK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Janus Kinase (JAK) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Janus Kinase (JAK) Inhibitors R&D. The therapies under development are focused on novel approaches for Janus Kinase (JAK) Inhibitors.
• June 2020: Gilead Sciences and Galapagos announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the double-blind, placebo-controlled, Phase 2 EQUATOR study and the EQUATOR-2 open-label extension study demonstrate filgotinib’s durable efficacy and consistent safety profile in people with active PsA, and showed rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe PsA. The new analyses were presented at the European League against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.

Janus Kinase (JAK) Inhibitors Report Insights

• Janus Kinase (JAK) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Janus Kinase (JAK) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Janus Kinase (JAK) Inhibitors drugs?
• How many Janus Kinase (JAK) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Janus Kinase (JAK) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Janus Kinase (JAK) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Japan Tobacco/LEO Pharma
• AbbVie
• Incyte Corporation
• Asana BioSciences
• Suzhou Zelgen Biopharmaceuticals

Key Products

• Gusacitinib